B+
Bull case
25%
Probability
Target price
$300.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
IQV
IQVIAANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$277.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$225.00
Analysis reference price unavailable
Analysis 2026-09-02 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-02
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+69.3
Score
AI commentary
Primary-company evidence is constructive after Q2 execution, higher bookings, backlog visibility, and raised FY2026 guidance [#SEC-8K-2026-07-28]. Stored secondary earnings context reports shares were up about 5.6% since the last earnings report, but detailed reaction attribution and analyst revisions are unavailable. Social coverage is unavailable, so confidence remains moderate.
RankAlpha Sentiment Codex - 2026-09-02
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-28eventQ2 execution and raised FY2026 guidanceMedium impact
IQVIA reported Q2 revenue of $4.368 billion, adjusted diluted EPS of $3.15, adjusted EBITDA of $994 million, and raised full-year 2026 revenue, EBITDA, and EPS guidance [#SEC-8K-2026-07-28].
2026-12-31catalystBacklog conversion and bookings durabilityMedium impact
R&D Solutions delivered 19% year-over-year net-new-bookings growth, a 1.22x book-to-bill ratio, and $34.2 billion of contracted backlog; approximately $9.2 billion is expected to convert to revenue over the next twelve months [#SEC-8K-2026-07-28].
2027-06-30catalystCommercial AI adoption and durable R&D demandHigh impact
Management cited increased adoption of AI-enabled offerings and favorable forward demand indicators across both segments; sustained adoption and bookings execution could support a longer-term rerating [#SEC-8K-2026-07-28].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-02 • Updated nightlySource: Internal modelMethodology